Table 4.
BCoV fluorescent focus reduction assay using strain-specific antibodies.
| BCoV strain (100 FFU) |
Neutralizing antibody titers to BCoV |
|||||||
|---|---|---|---|---|---|---|---|---|
| IgY to Arg95 |
IgY to Mebus |
Chicken serum to Arg95 | Chicken serum to Mebus | Guinea pig serum to Arg95 | Guinea serum to Mebus |
|||
| Crude egg yolk | Purified IgY | Crude egg yolk | Purified IgY | |||||
| Arg95 | 2.31 ± 0.35 | 3.91 ± 0.00 | 2.71 ± 0.00 | 4.21 ± 0.43 | 2.71 ± 0.00 | 3.51 ± 3547 | 2.91 ± 0.70 | 2.11 ± 0.00 |
| Mebus | 2.31 ± 0.35 | 3.91 ± 0.00 | 2.71 ± 0.00 | 4.21 ± 0.43 | 2.71 ± 0.00 | 3.51 ± 3547 | 2.91 ± 0.70 | 2.11 ± 0.00 |
A fourfold dilution of each sample (purified IgY, crude egg yolk, chicken serum and guinea pig serum) derived from animals vaccinated with inactivated BCoV strain Arg95 and Mebus was mixed with an equal volume of BCoV containing 100 FFU of each strain. Ab titers to BCoV were expressed as the inverse of the highest sample dilution (log10) reducing >80% of the number of fluorescent focus forming units (FFU) of each BCoV strain.